Who is sponsoring PERIGLUC1?

PERIGLUC1 is sponsored by Centre Hospitalier Universitaire, Amiens.

What condition does PERIGLUC1 study?

PERIGLUC1 studies Peritonitis Infectious, Candida Infection.

What drugs are being tested in PERIGLUC1?

Interventions: To evaluate the initial levels and kinetics of serum β-D-glucan.

What is the status of PERIGLUC1?

PERIGLUC1 is currently COMPLETED.

Last reviewed 2025-09-19 · How we verify

Kinetics of Serum β-D-glucan During Peritonitis With Candida in Resuscitation (PERIGLUC1)

NCT03140748 NA COMPLETED

Intraabdominal fungal infections with Candida are constantly increasing. Their diagnosis and treatment is difficult. Morbidity and mortality are high. Β-D-Glucan has been proposed as a marker of systemic fungal infection in candidemia. Moreover, its kinetics is associated with therapeutic success. On the other hand, there are no data on intraabdominal infections that are much more frequent. The objective of the study is to evaluate the initial levels of β-D-glucan and its daily kinetics during the treatment of fungal peritonitis in resuscitation compared to a control group with a yeast-free peritonitis.

Details

Lead sponsor	Centre Hospitalier Universitaire, Amiens
Phase	NA
Status	COMPLETED
Enrolment	70
Start date	Tue May 01 2018 00:00:00 GMT+0000 (Coordinated Universal Time)
Completion	Thu Jun 01 2023 00:00:00 GMT+0000 (Coordinated Universal Time)

Conditions

Peritonitis Infectious
Candida Infection

Interventions

To evaluate the initial levels and kinetics of serum β-D-glucan

Countries

France